| Literature DB >> 34661083 |
Takuya Kato1, Ryuhei Okada1, Yuto Goto2, Aki Furusawa1, Fuyuki Inagaki1, Hiroaki Wakiyama1, Hideyuki Furumoto1, Dagane Daar1, Baris Turkbey1, Peter L Choyke1, Hideo Takakura2, Osamu Inanami3, Mikako Ogawa2, Hisataka Kobayashi1.
Abstract
Near-infrared photoimmunotherapy (NIR-PIT) employs molecularly targeted antibodies conjugated with a photoabsorbing silicon-phthalocyanine dye derivative which binds to cancer cells. Application of NIR light following binding of the antibody-photoabsorber conjugates (APCs) results in ligand release on the dye, dramatic changes in solubility of the APC-antigen complex, and rapid, irreversible cell membrane damage of cancer cells in a highly selective manner, resulting in a highly immunogenic cell death. Clinically, this process results in edema after treatment mediated by reactive oxygen species (ROS). Based on the chemical and biological mechanism of NIR-PIT cytotoxicity and edema formation, in order to minimize acute inflammatory edema without compromising therapeutic effects, l-sodium ascorbate (l-NaAA) was administered to quench harmful ROS and accelerate the ligand release reaction. l-NaAA suppressed acute edema by reducing ROS after NIR-PIT yet did not alter the therapeutic effects. NIR-PIT could be performed safely under existence of l-NaAA without side effects caused by unnecessary ROS production.Entities:
Year: 2021 PMID: 34661083 PMCID: PMC8506607 DOI: 10.1021/acsptsci.1c00184
Source DB: PubMed Journal: ACS Pharmacol Transl Sci ISSN: 2575-9108